Letter regarding “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

2024-9-12

Correspondence on Editorial regarding “Spotting Undiagnosed Significant Liver Fibrosis in the General Population: Impact on Subsequent Clinical Care”

2024-9-11

Correspondence on Editorial regarding “KCTD17 as a RAS stabilizer in hepatocellular carcinoma progression”

2024-9-10

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD

2024-9-10

Correspondence on Letter regarding “A complement to epigenetics in MASLD”

2024-9-10

Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors

2024-9-3

Spotting Undiagnosed Significant Liver Fibrosis in the General Population: Impact on Subsequent Clinical Care

2024-9-3

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma

2024-9-2

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response

2024-8-30

Identification of KCTD17 as a RAS stabilizer in hepatocellular carcinoma

2024-8-30

Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers

2024-8-30

Reply to: “From invasive to intuitive: the emerging role of non-invasive models in hepatic decompensation”

2024-8-30

Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: a multi-nationwide cohort study from South Korea, Japan, and the UK

2024-8-29

Correspondence on Editorial regarding “Incretin-based therapy in the management of MASLD: one piece of the puzzle”

2024-8-27

TM6SF2 and PNPLA3: a potential dynamic duo?

2024-8-27

Leukocyte Telomere Shortening in MASLD and All-cause/Cause-specific Mortality

2024-8-27

A complement to epigenetics in MASLD

2024-8-27

The prognostic impact of psychiatric intervention on alcohol-associated liver disease : the UK Biobank cohort study

2024-8-27

Reply to correspondence on "Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging"

2024-8-27

Optimal cut-offs of transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis

2024-8-21

Diagnostic Accuracy of Transient Elastography for Staging Liver Fibrosis in Autoimmune Liver Diseases: A Systematic Review and Meta-Analysis

2024-8-21

Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using transient elastography: A systemic review and meta-analysis

2024-8-21

KASL Clinical Practice Guidelines for Noninvasive Tests to Assess Liver Fibrosis in Chronic Liver Disease

2024-8-19

Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease

2024-8-19

From Invasive to Intuitive: The Emerging Role of Non-Invasive Models in Hepatic Decompensation

2024-8-19

Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?

2024-8-19

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation

2024-8-19

Reply to correspondence regarding “Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions”

2024-8-19

Non-invasive prediction of post-sustained virological response HCC in HCV: A systematic review and meta-analysis

2024-8-12

Congratulatory remarks

2024-8-8

Preface

2024-8-8

Preface

2024-8-8

Congratulatory remarks

2024-8-8

MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors

2024-8-7

Presence of liver fibrosis in chronic hepatitis B patients with varying serum HBV DNA levels

2024-8-7

Development and Validation of a Stromal-Immune Signature to Predict Prognosis in Intrahepatic Cholangiocarcinoma

2024-8-6

KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression

2024-8-5

Reply to: “Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis”

2024-8-5

Correspondence to editorial on "Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study"

2024-8-5

MASLD across women’ reproductive lifespan and issues

2024-8-5

Precision medicine and nucleotide-based therapeutics to treat MASH

2024-8-5

Reply to correspondence regarding “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma

2024-8-5

From Past to Pandemic: Health Disparities in U.S. Hepatobiliary Cancer Mortality Before and During COVID-19

2024-8-5

Reply to: Association between serum HBV DNA levels and liver fibrosis in patients with chronic hepatitis B

2024-8-5

Differences in Major Adverse Cardiovascular Events of Nonalcoholic Fatty Liver Disease by Race and Ethnicity

2024-8-5

Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis

2024-7-30

Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions

2024-7-29

Reply to correspondence on Correspondence regarding "Reply to: “Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind”"

2024-7-29

Dynamic change of MASLD in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan

2024-7-29

Correspondence on Editorial regarding “Elimination of viral hepatitis: How far are we?”

2024-7-29